Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

Overview of attention for article published in BMC Cancer, November 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 63 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 3,975 followers.

#PubSaludMurcia Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study https://t.co/0m4PtnY7vd

22 Mar 2019

Reply Repost Favourite

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. https://t.co/j8TkhER4ju

05 Dec 2018

Reply Repost Favourite

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study PubMed - NCBI https://t.co/rU4vZ9Gezy #publiCHT

04 Dec 2018

Reply Repost Favourite

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study https://t.co/wMjBkxhDCW

29 Nov 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.